

ABSTRACT OF THE DISCLOSURE

5 The present invention provides compounds which have a  
pyrazinone or pyridinone ring at P3 and an optionally substituted  
heteroaryl group at P1. These compounds have biological activity  
as active and potent inhibitors of thrombin. Their  
pharmaceutically acceptable salts, pharmaceutical compositions  
10 thereof and methods of using these compounds and pharmaceutical  
compositions comprising these compounds as therapeutic agents for  
treatment of disease states in mammals which are characterized by  
abnormal thrombosis are also described.